Fig. 3.
BsAb-treated mice develop long-lasting antitumor protection.
The survival of mice is shown after donation of 5 × 103B16-EpCAM cells intraperitoneally on day 0 followed by the application of 10 μg bsAb BiLu (▪) on day 2 and another 5 μg on days 4 and 7. The control group received no antibody (+). Mice surviving the first tumor challenge (14 of 18 mice) were rechallenged on day 144 with a minimal lethal dose of 750 B16-EpCAM cells intraperitoneally. This time no bsAb treatment was performed. Whereas all control mice (n = 5) developed a tumor (not shown), mice pretreated with the bsAb BiLu successfully rejected the second tumor challenge. The experiment was repeated twice with similar results.
